The Science of Saving Lives

about-pic-1_1
about-pic-2_1
about-pic-3
about-pic-4_1

About

Sensei Biotherapeutics is developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. We are utilizing two drug discovery approaches. The first approach is our TMAb™️ (Tumor Microenvironment Activated biologics) platform comprised of human monoclonal antibodies and alpaca-derived nanobodies that are selectively active in the tumor microenvironment. Our lead program is targeting VISTA, a promising immune checkpoint inhibitor expressed on myeloid cells. Emerging nonclinical evidence has demonstrated that interaction of VISTA with its receptor (PSGL-1) is significantly enhanced by the acidic tumor microenvironment – a important differentiator of our research. We’re focused on unlocking the potential of VISTA with a human antibody and designed SNS-101 that selectively binds VISTA at low pH to activate T-cells and avoids on-target/off-tumor side effects, in preclinical studies.

The second approach is our ImmunoPhage™️ platform, that generates powerful, self-adjuvanted, and specific immune responses.

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Robert Pierce, M.D.

Chief Scientific Officer

John K. Celebi, M.B.A.

President and CEO

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics Announces Executive Promotions

    Company names Erin Colgan as chief financial officer and Robert Pierce, M.D. as chief R&D officer BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,Read More

  • Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award

    BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has won a Comparably award for 2021 “Best CEOs.” “What makes Comparably awardsRead More

  • Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index

    BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it was added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior toRead More

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics Announces Executive Promotions

    Company names Erin Colgan as chief financial officer and Robert Pierce, M.D. as chief R&D officer BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,Read More

  • Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award

    BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has won a Comparably award for 2021 “Best CEOs.” “What makes Comparably awardsRead More

  • Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index

    BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it was added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior toRead More

Signup For Update

sign up for newsletter and get the latest update